TOKYO —

A groundbreaking study from the University of North Carolina (UNC) School of Medicine is poised to reshape our understanding of Inflammatory Bowel Disease (IBD), suggesting that a common compound found in everyday healthy foods like spinach, almonds, and sweet potatoes may play a more significant role in exacerbating intestinal inflammation than previously understood. While these foods are lauded for their nutritional benefits, new research published on August 13, 2026, in Cellular and Molecular Gastroenterology and Hepatology (CMGH) indicates that for individuals battling IBD, dietary oxalate could be a key, yet overlooked, contributor to the chronic inflammation that characterizes these debilitating conditions.

Unraveling the Oxalate Connection: A Comprehensive Investigation

The extensive research, spearheaded by postdoctoral scholar Anna Salvador, PhD, RD, LDN, under the guidance of Professor Shehzad Z. Sheikh, MD, PhD, from the UNC Department of Medicine and Genetics, delved into the complex interplay between diet, gut physiology, and IBD. The study employed a multi-pronged approach, examining gene activity, the levels of oxalate present in stool samples, and the dietary patterns of both IBD patients and a control group of healthy individuals. To further solidify their findings, the researchers conducted rigorous experiments in both mouse models and human cell cultures, aiming to elucidate how dietary oxalate might directly influence the inflammatory processes within the intestinal lining.

The Gut’s Compromised Defenses: Impaired Oxalate Transport in IBD

Oxalate, a naturally occurring organic acid, is a ubiquitous component of virtually all plant-based foods. In a healthy digestive system, the body is adept at managing oxalate, with the vast majority passing through the gastrointestinal tract and being efficiently eliminated in the stool. However, the UNC study uncovered a critical vulnerability in individuals with IBD: a significant reduction in the expression of two key transporter proteins, SLC26A2 and SLC26A3. These proteins are crucial for the effective removal of oxalate from the gut.

The research revealed that these vital transporter proteins were consistently found at lower levels in intestinal tissues from patients diagnosed with both ulcerative colitis and Crohn’s disease, two primary forms of IBD. This diminished presence was observed across affected tissues, irrespective of whether active inflammation was currently present. Furthermore, the study noted a direct correlation: the more severe the inflammation in the intestinal tissue, the lower the expression of these oxalate transporters tended to be.

This impairment of the oxalate transport system has profound implications. When these mechanisms are compromised, the gut’s ability to absorb dietary oxalate is reduced. This leaves an increased amount of oxalate circulating within the intestinal environment. The new findings strongly suggest that this excess oxalate can then act as an irritant, potentially amplifying the pre-existing inflammation that is the hallmark of IBD.

Striking Discrepancies: Oxalate Levels in Crohn’s Disease Patients

One of the most compelling and unexpected discoveries of the study pertained to patients with Crohn’s disease. These individuals exhibited significantly higher levels of oxalate in their stool compared to their healthy counterparts, even when both groups reported consuming similar quantities of plant-based foods. This finding challenged the prevailing assumption that dietary oxalate accumulation is solely a consequence of high dietary intake.

To arrive at this conclusion, the researchers utilized two distinct methodologies. The first involved a validated dietary questionnaire, the Diet History Questionnaire III, which provided a detailed account of participants’ food consumption. The second, and perhaps more innovative, approach employed DNA metabarcoding. This advanced molecular technique allowed researchers to identify the specific plant species present in stool samples, offering an objective measure of dietary intake rather than relying solely on self-reporting. This marks the first instance where DNA metabarcoding has been applied to assess diet within an IBD population.

"For the first time, we observed that IBD patients and healthy controls were eating similar amounts of plant-based foods yet CD patients still had more oxalate in their stool," stated Dr. Salvador, underscoring the significance of this revelation. "That told us this isn’t just about what patients eat. Something is fundamentally different about how their gut handles oxalate." This observation strongly implies that elevated oxalate in the intestines of IBD patients is less about the quantity of oxalate consumed and more about a fundamental biological deficiency in how the gut processes it.

Animal Models Reinforce the Link: Oxalate as an Inflammatory Amplifier

To further validate the association between dietary oxalate and IBD, the researchers conducted a series of experiments using various animal models. These studies provided critical evidence supporting the hypothesis that oxalate can indeed exacerbate intestinal inflammation.

In one experiment, mice that were administered a diet supplemented with oxalate, in conjunction with a substance known to induce colitis (a form of IBD), demonstrated a striking 60% decrease in survival rates compared to mice that did not receive the additional dietary oxalate. This suggests a direct and detrimental impact of oxalate on disease severity and survival.

Further experiments involved two distinct mouse models that were genetically predisposed to developing spontaneous colitis. In these susceptible mice, the introduction of dietary oxalate not only accelerated the onset of the disease but also significantly increased its severity. Crucially, the researchers observed that the genes responsible for oxalate transport were already exhibiting reduced activity in these genetically prone mice, even before oxalate was added to their diets. This pattern mirrored the findings in human IBD patients, reinforcing the concept of a pre-existing biological vulnerability.

In vitro experiments using cultured cells provided additional mechanistic insights. Oxalate was found to intensify inflammatory responses in macrophages and dendritic cells, critical immune cells that play vital roles in maintaining intestinal health and regulating immune responses. This indicates that oxalate can directly activate inflammatory pathways within the immune system.

A Potential Biomarker for Disease Progression: Oxalate Transporter Activity

Beyond its role in exacerbating inflammation, the UNC research also explored whether oxalate-related gene activity could serve as an indicator of how Crohn’s disease progresses. In an exploratory analysis, the team discovered a significant association between low expression of another transporter protein, SLC26A6, and stricturing Crohn’s disease. Stricturing Crohn’s is a more aggressive and debilitating form of the condition characterized by the buildup of scar tissue, leading to narrowing of segments of the intestine.

The findings revealed that nearly 75% of patients with low SLC26A6 expression also presented with stricturing disease. This compelling correlation opens the possibility that the activity of oxalate transporter genes could, in the future, assist clinicians in identifying patients at a higher risk of developing more severe and complicated forms of Crohn’s disease. However, the researchers emphasized that this finding is preliminary and requires confirmation in larger, more diverse patient cohorts before it can be considered a reliable clinical marker.

Dr. Sheikh lauded Dr. Salvador’s initiative and rigor in pursuing this novel line of inquiry. "Dr. Salvador really conceptualized and drove this work from the beginning," he commented. "She asked a question that hadn’t been asked before: What if a specific dietary molecule is an active driver of gut inflammation in IBD, not just a bystander? The rigor she brought to answering it is what makes these findings so compelling."

Implications for Individuals with IBD: Navigating Diet and Future Treatments

The implications of these findings for individuals living with IBD are significant, though the researchers were careful to temper expectations. Crucially, the study does not advocate for the complete elimination of plant-based foods from the diets of IBD patients. These foods remain essential sources of vital nutrients.

Instead, the research suggests that in individuals with a genetic predisposition, even moderate amounts of oxalate found in these healthy foods may contribute to the chronic inflammation of the intestinal lining. Furthermore, the study proposes that previous dietary research in IBD may have been confounded by variations in how individual patients absorb and process oxalate, leading to inconsistent results.

The findings also open avenues for dietary management. It remains feasible for individuals with IBD to maintain a nutritionally complete, plant-rich diet while strategically reducing their overall oxalate intake. This could involve mindful food choices and preparation methods known to lower oxalate levels.

Beyond dietary modifications, the gut microbiome presents another promising frontier for therapeutic intervention. Certain species of intestinal bacteria, notably Oxalobacter formigenes, possess the remarkable ability to break down oxalate. Research indicates that these beneficial bacteria are less abundant in individuals with IBD. This observation raises the exciting prospect of future microbiome-based treatments designed to enhance oxalate breakdown within the gut. Such therapies could offer an alternative or complementary approach to relying solely on dietary restrictions, potentially improving gut health for IBD patients.

The Road Ahead: Rigorous Research and Evolving Guidelines

Despite the compelling nature of their findings, the UNC researchers stressed that the current body of evidence is not yet sufficient to warrant formal recommendations regarding oxalate intake for individuals with IBD. They emphasized the critical need for further, more extensive research.

Future studies are envisioned to follow larger patient cohorts over extended periods. These longitudinal studies will aim to integrate comprehensive measurements, including stool oxalate levels, meticulously documented dietary intake, detailed molecular profiling, and in-depth microbiome analyses. This holistic approach will be crucial for solidifying the link between oxalate, gut health, and IBD progression.

"For patients living with Crohn’s disease or ulcerative colitis, this research opens a genuinely new therapeutic angle – one that connects the food on their plate to the inflammation in their gut," stated Dr. Sheikh, highlighting the transformative potential of this work. "Diet is one of the most powerful, modifiable levers we have in medicine, and this study gives us a molecular framework to start using it more precisely."

The research was generously supported by grants from the Helmsley Charitable Trust, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Chan Zuckerberg Initiative, Schmidt Sciences, the Burroughs Wellcome Fund, and additional funding from the National Institutes of Health. Collaborative efforts on this study spanned researchers from UNC-Chapel Hill, Texas A&M University, and Duke University, underscoring a broad and dedicated scientific commitment to unraveling the complexities of IBD. As research continues, the focus on specific dietary components like oxalate offers a tangible and potentially powerful new strategy in the ongoing fight against inflammatory bowel diseases.